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A B S T R A C T
Objectives: Excessive weight gain associated with valproate sodium (VPA) may predispose patients with
epilepsy to other health problems such as insulin resistance. The purpose of this study was to examine
the changes in body weight and several biochemical parameters in children receiving VPA treatment.
The effects of behavior therapy for epileptic children with VPA-induced weight gain are discussed.
Methods: Fifteen patients newly diagnosed with epilepsy were included in the study. The following
parameters were measured: body weight, body mass index (BMI), serum glucose, serum insulin, serum
VPA concentration and serum free carnitine. In addition, behavior therapy was introduced at the
initiation of VPA therapy, and lasted at least for 2 years.
Results: After 6 months of follow-up, there were eight (53%) patients in whom weight gain was
demonstrated. Signiﬁcant increases in the serum insulin level and the insulin/glucose ratio were
observed in the weight gain group (p < 0.01). All patients with signiﬁcant weight gain showed increased
appetite. However, BMI stopped increasing with intensive behavior therapy.
Conclusions: These ﬁndings suggest that an increase in serum insulin and insulin/glucose levels may
cause weight gain, possibly by stimulating appetite, and that weight changes seem to be reversible with
intensive behavior therapy without discontinuation of VPA.
 2012 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Valproate sodium (VPA) is a broad-spectrum anticonvulsant.
VPA is not a sedative and it is associated with fewer cognitive or
behavioral effects than other drugs such as phenobarbital.1 On the
other hand, VPA causes numerous side effects.2 Patients with
chronic epilepsy treated with VPA did not self-report any
improvement in health-related quality of life.3 Moreover, use of
VPA in patients with epilepsy is associated with an increase in body
weight that can interfere with treatment compliance.
Weight gain is a well-known adverse effect of VPA treatment,
occurring in 40% of children.4 Weight gain is the most common
reason for patients to discontinue VPA treatment.5–7 In a recent
study, 38% of VPA-treated patients gained more than 10% of their
body weight compared with 8% of patients treated with
lamotrigine.8 Further, weight gain associated with VPA seems
to be appetite-related and not metabolic.9 Although there has
been recent interest in weight gain accompanying VPA therapy,* Corresponding author at: Department of Pediatrics, Faculty of Medicine,
University of Yamanashi, 1110 Chuo, Yamanashi 409-3898, Japan.
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1059-1311/$ – see front matter  2012 British Epilepsy Association. Published by Else
http://dx.doi.org/10.1016/j.seizure.2012.05.001the pathogenic mechanisms of this adverse effect remain unclear.
In the study by Isojarvi et al., hyperandrogenism and polycystic
ovaries were associated with weight gain, elevated fasting serum
insulin levels, and serum low insulin-like growth factor-binding
protein 1 (IGFBP-1) levels in women taking VPA for epilepsy.10
These ﬁndings suggest that the weight gain can be progressive and
is associated with hyperinsulinemia and low serum IGFBP-1
levels, which may lead to hyperandrogenism and polycystic
ovaries. Thus, hyperinsulinemia may cause weight gain in
patients taking VPA.
Many adverse health effects generally associated with adult
obesity are now being seen in obese adolescents.11,12 Behavior
therapy is a psychological treatment based on the theory that the
problem in question is maintained by certain dysfunctional
cognitions and beliefs.13,14 Basic components of behavior therapy
are changing a child’s eating habits, providing a moderate exercise
program, implementing self-regulation skills and providing
parental and peer support.15 Excessive weight (e.g., obesity) is a
complex interplay of environmental, social, economic, and
behavioral factors, acting on the background of genetic suscepti-
bility. Therefore, weight-control interventions are multifaceted
and excessive weight or weight gain not simply treatable with
behavior therapy. However, successful weight management may
be possible without strict diet prescriptions.16,17vier Ltd. All rights reserved.
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weight and several biochemical and endocrine parameters in older
children and adolescents receiving VPA treatment. In addition, the
effect of behavior therapy on VPA-induced weight gain is
discussed.
2. Patients and methods
Fifteen patients (5 males and 10 females, mean age 11.1 years,
range 7–16 years of age) newly diagnosed with epilepsy and for
whom VPA was considered the most suitable treatment18 were
included in the study after informed parental consent was
obtained. Patients were referred to the University of Yamanashi
Hospital and its satellite hospitals between April 1, 2003 and
March 31, 2005. Seven patients had idiopathic generalized
epilepsy, and eight patients had idiopathic partial epilepsy with
secondary generalization. Brain magnetic resonance imaging or
computed tomographic scans were interpreted as normal. The
average daily dose of VPA was 17.4 mg/kg (range, 13.6–23.1 mg/
kg). No patients required other anticonvulsants in addition to VPA.
Participants were included if their weight and height were
documented at the initiation of VPA treatment and if they returned
for at least one follow-up visit during which their weight and
height were re-measured. Those who were followed up for fewer
than 3 months or who discontinued VPA treatment within 3
months of initiation, were excluded. Patients were also excluded if
they received concurrent medication known to affect weight, such
as antipsychotic agents, or stimulants.
The main screening assessments included seizure frequency,
vital signs, physical and neurologic examinations, medical history,
and standard clinical laboratory tests. Weight and height
measurements were recorded at the initiation of VPA therapy
and at all scheduled visits. Body mass index (BMI) was calculated at
each of these points by dividing the weight in kilograms by the
square of the height in meters. National growth chart ﬁndings
based on data collected in a survey of Japanese children were used
to obtain the mean body weight for height. The BMI category was
deﬁned as underweight, <18.5, appropriate, 18.5–21.5, potentially
overweight, 21.5–25.0 and overweight, >25.0. Patients with a BMI
increase exceeding 1.0 per 3 months were categorized in the
weight gain group. In addition, we asked participants about
appetite using the question ‘‘Has your appetite increased or
decreased since starting the treatment?’’
A blood sample was obtained between 8:30 and 9:00 am after
an overnight fast and before breakfast. Weight and height were
measured at the same time. The following parameters were
measured using commercially available radioimmunoassay kits:
serum glucose, serum insulin, serum VPA concentration, serum-
free carnitine, triiodothyronine, thyroxine, thyroid-stimulating
hormone, high-density lipoprotein cholesterol, and low-density
lipoprotein cholesterol.
Potential predictors of BMI category at follow-up and BMI
difference, including age at initiation of VPA, gender, VPA dose per
weight (average maintenance dose, highest dose used), and
average serum level, were recorded. The assessment was
performed every 3 months.
The behavior therapy intervention was carried out by a
pediatric neurologist trained in behavior therapy. Oral instruction
for avoidance of weight gain was introduced to all patients at the
initiation of VPA therapy. Our oral instructions for avoiding weight
gain included the evidence that weight gain may cause metabolic
and psychological problems. Further, programed behavior therapy
was introduced to the weight-gainers at 6 months after VPA
initiation. The intervention was conducted through work with
both the children and their parents. The program of behavior
therapy was based on lifestyle modiﬁcation using a simplechecklist.19 Asayama et al. previously reported that the majority
of the boys and nearly half of the girls participating in behavior
therapy for longer than 200 days grew out of their obesity.20 The
behavior strategies consisted of several instructions as follows: (1)
children and their families were instructed to regularly to eat three
meals and one afternoon snack daily, avoiding intake of extra
snacks, juices, oily (greasy) food additives, sugar and candies, and
to drink no more than 200 ml of milk; (2) reduced caloric intake
was not prescribed but patients were advised to observe the
recommended daily allowance of food energy for each age and sex
set by the Ministry of Education, Science and Culture of Japan; (3)
children were instructed to play video or computer games for no
more than 1 h a day; and (4) each child (or family) kept a checklist
to evaluate (yes or no) whether they observed the seven
recommendations (three meals and a snack, no night eating,
video game limitations and doing their chores, etc.) on a daily
basis. They reported their checklist scores (max. 7 points  7 days
per week) once every 3 months. We instructed the family on these
points repeatedly at each visit (every 3 months). In this treatment
program, diet was not restricted and ﬁxed exercise regimes were
not prescribed. Therefore, weight gain or excess were essentially
intended to be ameliorated by life style modiﬁcation with a modest
change in body weight.19 There was no other psychoeducational
component to the intervention. The duration of behavior therapy
was 15 min per session. The sessions were delivered as part of the
routine epilepsy visit every 3 months. The behavior therapy was
intensiﬁed as a result of participant or parental feedback from the
checklist. The maximum-minimum frequency and duration of
sessions was every 2–3 months and 15–30 min per session,
respectively. The behavior therapy intervention lasted for at least
two years.
We collected other data every 3 months in addition to the
family’s report of their adherence to recommendations. We
assessed whether patients report their appetite as increased or
decreased via the ‘‘appetite increased’’ question from the
participants’ reports. All data are presented as means for each
group measure. The BMI difference for the two groups and the
comparison between the two groups of patients was performed
using ANOVA and Dunnett’s test when appropriate. For statistical
analysis, a p-value <0.05 was deﬁned as statistically signiﬁcant.
3. Results
We followed all patients from the beginning of therapy for at
least two years. In the six months after the ﬁrst observation, there
were eight (53%) patients in whom weight gain was demonstrated
(deﬁned as an increase of BMI >1.0 in 3 months). However, no
patients remained in the weight gain group at the end of the
follow-up. Therefore, we subdivided the patients into two groups
according to their BMI halfway through behavior therapy. Behavior
therapy lasted for at least two years. Patient data are summarized
in Table 1. There were no signiﬁcant differences in body weight and
BMI at VPA initiation between the weight gain (n = 8; mean age,
11.9 years; age range, 8–16 years: male:female = 0:8) and no
weight gain groups (n = 7; mean age, 10.1 years; age range, 7–13
years; male:female = 5:2). However, the difference in BMI became
signiﬁcant during the course of the study (p < 0.01). Therefore, this
subdivision was appropriate. We observed excellent seizure
control with complete disappearance of seizures after 2 months
of therapy in all patients in both groups. Thus, the severity and
frequency of seizures were similar in the two groups. All patients
remained seizure free until the end of the study. No patients
required additional anticonvulsant medication during the study.
The mean BMI was 19.1 at initiation of VPA therapy for the
entire sample (S.D., 2.4; range, 15.8–22.9). At onset, six (40.0%)
subjects were in the underweight range, seven (46.7%) were in the
Table 1
Patient data.





















BMI (kg/m2) 20.03 21.19 22.09 20.75 20.08 17.94 17.96 17.77 17.86 17.83
Serum glucose (mg/dl) 84.75 89.13 93.13 89.25 87 84.57 85.71 88 86.57 86
Serum insulin (mU/ml) 11.28 15 16.83 14.48 13.28 10.39 10.56 10.56 10.44 10.59
Serum insulin to glucose ratio 0.133 0.169 0.181 0.163 0.153 0.123 0.123 0.12 0.121 0.123
Serum VPA concentration (mg/ml) n.d. 65.55 64.18 66.93 68.4 n.d. 69.81 69.91 69.49 69.7
Serum carnitine (mmol/l) 44.75 43.38 44.75 44.38 44.08 40.21 41.74 42.01 41.57 42.13
BMI, body mass index; VPA, valproate sodium; n.d., not done.
Fig. 2. Serial changes in the mean BMI. BMI in the weight gain group increased
within 6 months after initiation of VPA treatment. However, the BMI decreased
after 6 months. At the end of the study (year 2), an analysis of BMI revealed no
signiﬁcant change before initiation of treatment. By contrast, no obvious change
was evident in the no weight gain group. Closed squares with solid lines indicate the
weight gain group. Closed circles with dotted lines indicate the no weight gain
group. Arrow indicates the onset of intensive behavior therapy.
H. Kanemura et al. / Seizure 21 (2012) 496–500498appropriate weight range, and two (13.3%) were potentially
overweight. The mean ﬁnal BMI at follow-up was 19.0 (S.D., 4.2;
range, 16.1–22.5), with seven (46.7%) in the underweight range,
ﬁve (33.3%) in the appropriate weight range and three (20.0%) in
the potentially overweight range. Children in overweight group at
baseline were more likely to put on weight than children of normal
weight or underweight children.
Weight change throughout the study during the drug treatment
phase is depicted in Fig. 1. A signiﬁcant increase in BMI was
observed within 6 months after initiation of treatment in the
weight gain group (Fig. 2). Weight gain occurred only in females,
with signiﬁcant differences between genders. Serum glucose,
serum insulin, serum insulin to glucose ratio, VPA concentration,
and serum carnitine are shown in Table 1. A signiﬁcant increase in
the insulin concentration was observed in the weight gain group
(p < 0.01) (Fig. 3a). Glucose levels did not change signiﬁcantly in
either group. No correlation between alterations in glucose levels
and weight gain was evident. The insulin/glucose ratio increased
signiﬁcantly in the weight gain group (p < 0.01) (Fig. 3b). All
patients with marked weight gain showed increased appetite.
Once behavior therapy had been intensiﬁed, however, the appetite
decreased subjectively. In addition, both discontinuation of body
weight increase and BMI decrease were seen after six months of
intense behavior therapy (Figs. 1 and 2). Checklist scores were also
increased (improved) after behavior therapy intensiﬁcation (mean
score 29.0 points/week before behavior therapy to 40.8 points/
week 1 year after behavior therapy initiation). At the end of the
study (year 2), BMI showed no signiﬁcant change from levels
measured before the initiation of treatment in both groups.Fig. 1. Serial changes in mean body weight in patients after initiation of treatment
with VPA. Body weight in the weight gain group increased within 6 months after
initiation of treatment. By contrast, body weight increase was gentle in the no
weight gain group. Closed squares with solid lines indicate the weight gain group.
Closed circles with dotted lines indicate the no weight gain group. Arrow indicates
the onset of intensive behavior therapy.No signiﬁcant changes in mean carnitine concentrations were
observed in any patients. No correlation was found between the
carnitine concentrations, serum levels of VPA, and weight gain.
Thyroid hormones, cholesterol, triglyceride levels, and liver
enzymes remained unchanged in all patients.
4. Discussion
In this study, a signiﬁcant increase in BMI was observed within
6 months after initiation of treatment in eight patients (53.3%).
Furthermore, our results demonstrated that the occurrence of
weight gain was more prevalent in females with epilepsy than in
males. This is consistent with previous ﬁndings suggesting that
VPA may induce weight gain in young women.21 In some children,
particularly adolescent girls, excessive weight gain has serious
psychological effects. Some patients develop substantial weight
gain on VPA, which can be treatment limiting.22 The patients in our
study did not develop substantial weight gain; however, this
problem must be addressed if medication for females with epilepsy
is begun before 20 years of age.
Various mechanisms have been proposed to explain the weight
gain associated with VPA treatment. An increased consumption of
food and energy-rich beverages because of an increased appetite
and abnormal thirst has been suggested.23,24 However, it appears
that VPA has no effect on the total intake of calories.25 In this study,
all patients with marked weight gain reported an increased
appetite. Thus, the factors contributing to weight gain during VPA
therapy are not completely understood and there are likely to be
multiple contributing factors, however, one factor may be
Fig. 3. Serial changes of mean serum insulin levels (a) and insulin/glucose ratio (b).
Serum insulin levels and insulin/glucose ratio in the weight gain group increased
within 6 months after initiation of VPA treatment. By contrast, no change was
evident in the no weight gain group. Closed squares with solid lines indicate the
weight gain group. Closed circles with dotted lines indicate the no weight gain
group. Arrow indicates the onset of intensive behavior therapy.
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increased insulin concentrations and insulin/glucose ratios were
observed. Higher insulin and insulin/glucose levels may be
involved in weight gain by stimulating appetite. On the other
hand, in the patients without weight gain, who showed no
increased appetite, no increase in serum insulin or insulin/glucose
levels was demonstrated. These ﬁndings suggest that an increase
in serum insulin and insulin/glucose levels may cause weight gain,
possibly by stimulating appetite. The ﬁndings of decreased insulin
levels within 2 months and body weight within 12 months suggest
that hyperinsulinemia may play a primary role in VPA-induced
metabolic changes.26
In our study, there were no signiﬁcant reductions in glucose
levels, consistent with a previous report.7 The lack of a correlation
between changes in insulin levels and glucose concentrations
suggests the effect of additional factors. In the presence of
palmoxirate, binding of VPA is decreased by a competitive
mechanism.27Methyl palmoxirate inhibited insulin release evoked
by several nutrient secretagogues.28 Moreover, methyl palmoxi-
rate also inhibited insulin release evoked by non-nutrient
secretagogues.29 These ﬁndings suggest the inhibitory action of
methyl palmoxirate on insulin release may be attributable to a
speciﬁc alteration of fatty acid oxidation rather than to an
unexpected side-effect of the drug.28 However, the study by
Verrotti et al. revealed that abnormal glucose homeostasis was
identiﬁed in 45% of patients.30 They also reported that VPA causes
metabolic syndrome in some patients, but not in all patients. In our
study, there were no excessive weight gainers. Our results showedno signiﬁcant changes in serum glucose levels and the lack of
weight gain may be related to that. Further research is needed to
clarify this point.
The results of the present study show these effects transiently
without replacement of VPA. There is some evidence that exercise
increases the long-term success rate, particularly if combined
with behavioral modiﬁcations to alter lifestyle.31 Any increase in
physical activity is good, especially if accompanied by a decrease
in sedentary activities such as watching television and playing
computer games. We encouraged the patients to visit our ofﬁce
regularly. In addition, we explained the treatment plan clearly and
the risks of adverse effects of drug therapy with VPA, including
risks associated with irregular drug intake. Our study is
prospective, and therefore anthropometric measures were
available at speciﬁed points. These ﬁndings showed that
successful weight management is possible for epileptic children
with VPA-induced obesity without replacement of VPA or difﬁcult
diet restrictions.
Most patients ﬁnd even modest weight gain unpleasant and
development of obesity may in some cases make VPA unaccept-
able to the patient. However, it is not our intent to discourage the
use of VPA. The results of the present study also show that in
addition to VPA-related metabolic alterations, weight changes
seem to be at least partially reversible by intense behavior therapy
without discontinuation of medication. The study by Verrotti et al.
has reported that metabolic syndrome is not caused by VPA
medication but is due to the weight gain induced by VPA
therapy.30 Therefore, the preventive treatment for weight gain
may be important. Our results are helpful to reassure children and
their parents that weight gain will not persist. However, Verrotti
et al. also have reported that feeding habits have apparently no
effects on the development of metabolic syndrome.30 Long-term
weight loss and weight maintenance in children and adolescents
can only be achieved if unhealthy eating and behavior are replaced
with healthier lifestyle changes that persist into adulthood.14
However, the results of child-directed treatments are disappoint-
ing in the long run.32 They concluded that the habits of the parents
have signiﬁcant effects on child and parent BMI. The behavior
therapy approach used in the present study did not recommend a
calorie-restricted diet, but rather encouraged healthy eating
habits for children and their families. This approach may have
helped to encourage the children. The programed behavior
therapy was introduced to the weight-gainers six months after
initiation of VPA treatment. However, a preventive treatment may
be needed before starting VPA therapy in high-risk patients. We
have recommended the behavior therapy approach used in the
present study from the beginning of VPA therapy in high-risk
patients.
As our understanding of the anticonvulsant mechanisms of
drugs like VPA increases, we should also try to learn more about
the mechanisms causing adverse effects and how these can be
prevented. Although the use of VPA is associated with weight gain,
it may still be the best option for treating some speciﬁc epilepsy
syndromes. Moreover, VPA is prescribed more frequently in
patients with psychiatric disorders.33 Concerns about potential
weight gain should be discussed with patients before VPA therapy
is begun and BMI should be monitored closely. These concerns
should not preclude the use of VPA. Nevertheless, our ﬁndings of
VPA-associated weight gain raise concerns about the use of VPA.
Successful weight management with behavior therapy may be
possible for epileptic children with VPA-induced obesity and
without replacement of VPA.
Our sample of patients was small and therefore we cannot make
deﬁnitive conclusions. Further research is necessary in this area
with a larger sample of patients and a better determination of the
intensity of behavior therapy that is needed.
H. Kanemura et al. / Seizure 21 (2012) 496–5005005. Conclusions
These ﬁndings suggest that an increase in serum insulin and
insulin/glucose levels may cause weight gain, possibly by
stimulating appetite, and that weight changes may be reversible
with behavior therapy without discontinuation of VPA.
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